683 Capital Management LLC acquired a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 56,850 shares of the company’s stock, valued at approximately $1,032,000.
Other hedge funds also recently made changes to their positions in the company. UBS Group AG raised its stake in shares of Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after purchasing an additional 432,608 shares during the period. Patient Square Capital LP purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $1,271,000. Moody Aldrich Partners LLC purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $2,419,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $1,083,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $3,432,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.
Insiders Place Their Bets
In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total value of $110,715.22. Following the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. This trade represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This represents a 52.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 112,586 shares of company stock valued at $2,089,651 over the last quarter. Insiders own 4.46% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Report on AVTX
Avalo Therapeutics Stock Performance
Shares of NASDAQ:AVTX opened at $15.40 on Thursday. The stock has a market capitalization of $809.58 million, a price-to-earnings ratio of -2.82 and a beta of 0.83. Avalo Therapeutics, Inc. has a 1-year low of $4.47 and a 1-year high of $24.27. The company’s fifty day moving average is $15.53 and its two-hundred day moving average is $16.12.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. Sell-side analysts expect that Avalo Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report).
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
